Demystifying the Role of Tumor Mutational Burden for Immunotherapy Selection - Reply

TY - JOUR

T1 - Demystifying the Role of Tumor Mutational Burden for Immunotherapy Selection - Reply

AU - Waqar, Saiama N.

AU - Govindan, Ramaswamy

N1 - Funding Information: Funding/Support: This work was supported by the National Health and Medical Research Council Program Grant (568971); and a Cancer Council New South Wales Strategic Research Partnership Program Grant (13–11). Cytological testing materials were provided by Hologic (Australia) Pty Ltd. Funding Information: Disclaimer: The Kirby Institute is affiliated with the Faculty of Medicine, University of New South Wales, and funded by the Australian Government of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government. Funding Information: Conflict of Interest Disclosures: Dr Waterboer serves on advisory boards for Merck Sharp & Dohme. Dr Poynten has received travel funding from Seqiris. Dr Jin reported grants from the Australian National Health and Medical Research Council and grants from Cancer Council New South Wales during the conduct of the study. Dr Grulich has received honoraria and research funding from CSL Biotherapies and honoraria and travel funding from Merck Sharp & Dohme. Dr Hillman has received support from CSL Biotherapies and Merck Sharp & Dohme. No other disclosures were reported. Funding Information: Conflict of Interest Disclosures: Dr Waqar reported receiving support through the UM1 CA186704-01 grant from the National Institutes of Health/National Cancer Institute and has served as institutional principal investigator for studies funded by AstraZeneca, AbbVie, F. Hoffmann-La Roche, Ariad, Pfizer, Hengrui Therapeutics, Xcovery, EMD Serono, Eli Lilly and Company, Stemcentrx, Ignyta Inc, Bristol-Myers Squibb, Synermore, Novartis, Merck, Celgene, NewLink Genetics Corp, Genentech, and Checkpoint Therapeutics. Dr Govindan reported serving on advisory boards for AbbVie, Inivata, Pfizer, Genentech, Bristol-Myers Squibb, Roche, Nektar, Merck, Celgene, Partner Therapeutics, GlaxoSmithKline, Jounce, and Achilles and serving as a consultant for AbbVie, Eli Lilly and Company, AstraZeneca, Pfizer, Genentech, Millennium Pharm, F. Hoffmann-La Roche, NeoHealth, Janssen, Amgen, and GenePlus. Funding Information: Conflict of Interest Disclosures: Mr Fabrizio reported being a stockholder in Roche and having a patent to Methods and Systems for Evaluating Tumor Mutational Burden, pending. Dr Hegde reported being an employee and stockholder of Roche and having a patent to Methods and Systems for Evaluating Tumor Mutational Burden (P31103-US-1), pending. Dr Alexander reported receiving personal fees from Foundation Medicine and Roche and grants from Eli Lilly and Company, Puma, and Celgene.

PY - 2020

Y1 - 2020

UR - http://www.scopus.com/inward/record.url?scp=85091425306&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2020.3397

DO - 10.1001/jamaoncol.2020.3397

M3 - Letter

C2 - 32880608

AN - SCOPUS:85091425306

VL - 6

SP - 1809

EP - 1810

JO - JAMA Oncology

JF - JAMA Oncology

SN - 2374-2437

IS - 11

ER -